Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - acalabrutinib 100 mg/1 cap - 100 mg/1 cap

Bangladesh - English - DGDA (Directorate General of Drug Administration)

incepta pharmaceuticals ltd. - acalabrutinib - capsule - 100 mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

beacon pharmaceuticals plc - acalabrutinib - capsule - 100 mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

everest pharmaceuticals ltd. - acalabrutinib - capsule - 100 mg

Philippines - English - FDA (Food And Drug Administration)

astrazeneca ab; distributor: astrazenecapharmaceuticals (phils.), inc. - acalabrutinib - capsule - 100 mg

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

astrazeneca k.k - acalabrutinib - blue and yellow capsule, major axis: approx. 19.4 mm, minor axis: approx. 6.9 mm

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

astrazeneca pharmaceuticals (pty) ltd - capsules - see ingredients - each capsule contains acalabrutinib 100,0 mg

Canada - English - Health Canada

gilead sciences canada inc - brexucabtagene autoleucel - suspension - 200000000cells - brexucabtagene autoleucel 200000000cells - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - brexucabtagene autoleucel, quantity: 1000000 cells/kg - injection, intravenous infusion - excipient ingredients: albumin; dimethyl sulfoxide; sodium chloride - cellular therapies - tecartus is a genetically modified autologous immunocellular therapy for the treatment of patients with relapsed or refractory mantle cell lymphoma (mcl), who have received two or more lines of therapy, including a btk inhibitor, unless ineligible or intolerant to treatment with a btk inhibitor.

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - brexucabtagene autoleucel, quantity: 1000000 cells/kg - injection, intravenous infusion - excipient ingredients: dimethyl sulfoxide; sodium chloride; albumin - cellular therapies - tecartus is a genetically modified autologous immunocellular therapy for the treatment of patients greater than or equal to 18 years of age with relapsed or refractory (r/r) b-cell acute lymphoblastic leukaemia (b-all).